Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

Abstract

In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension of this study. In the extension (months 7—36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose. During months 15—24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg. Of the 250 patients who entered the extension study, 173 (69%) continued to month 36. Most patients were free from gadolinium-enhanced lesions (88—89%) or new T2 lesions (70—78%) at month 36. Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20—0.21, and 68—73% remained relapse-free at month 36. Over 36 months, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events. Pulmonary function remained stable and blood pressure was stable after an initial increase (3—5 mmHg) during the first 6 months of fingolimod treatment; serious adverse events included infections and skin cancer. The low MRI and clinical disease activity at 6 months were maintained at 36 months with fingolimod, which was generally well tolerated by most patients. The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study programme.

Keywords

Fingolimod FTY720 multiple sclerosis MRI oral sphingosine 1-phosphate

Get full access to this article

View all access options for this article.

References

Adachi K. , Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology . Perspect Medicin Chem 2007; 1: 11-23.

Matloubian M. , Lo CG , Cinamon G. , et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.

Pinschewer DD , Ochsenbein AF , Odermatt B. , Brinkmann V. , Hengartner H. , Zinkernagel RM FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory . J Immunol 2000; 164: 5761-5770.

Mandala S. , Hajdu R. , Bergstrom J. , et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.

Mehling M. , Brinkmann V. , Antel J. , et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267.

Wheeler D. , Bandaru VV , Calabresi PA , Nath A. , Haughey NJ A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131: 3092-3102.

Miron VE , Jung CG , Kim HJ , Kennedy TE , Soliven B. , Antel JP FTY720 modulates human oligodendrocyte progenitor process extension and survival . Ann Neurol 2008; 63: 61-71.

Dev KK , Mullershausen F. , Mattes H. , et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117: 77-93.

Choi JW , Herr D. , Lee C-W. , Teo S. , Kennedy G. , Chun J. S1P1 receptor signaling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and efficacy of fingolimod (FTY720). Mult Scler 2008; 14: (abstract).

10.

Kappos L. , Antel J. , Comi G. , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.

11.

O’Connor P. , Comi G. , Montalban X. , et al. Two-year experience with oral fingolimod (FTY720) in multiple sclerosis: extension of a randomized phase II trial. Neurology 2009; 72: 73-79.

12.

McDonald WI , Compston A. , Edan G. , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

13.

Kappos L. , Lechner-Scott J. , Lienert C. Neurostatus training and documentation CD-ROM for a standardized neurological examination and assessment of Kurtzke’s functional systems and expanded disability status scale for MS patients. Basel, Switzerland: Point de Vue Audiovisuelle Produktionen, 2003.

14.

Salvadori M. , Budde K. , Charpentier B. , et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006 ; 6: 2912-2921.

15.

Pike GB , De Stefano N. , Narayanan S. , et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 2000; 215: 824-830.

16.

Wolfe F. , Michaud K. , Chakravarty EF Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370-1375.

17.

Hofmann M. , Brinkmann V. , Zerwes HG FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006; 6: 1902-1910.

18.

Brinkmann V. , Cyster JG , Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-1025.

19.

Brinkmann V. , Mitruecker H. , Jenner N. , Metzler B. The mode of action of FTY720 (fingolimod), an oral sphingosine-1-phosphate receptor modulator that is highly effective in human multiple sclerosis (Phase II). Mult Scler 2006; 12: (abstract).